help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christian, R. C.
Right arrow Articles by Fitzpatrick, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christian, R. C.
Right arrow Articles by Fitzpatrick, L. A.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 3 1062-1067
Copyright © 2002 by The Endocrine Society


Endocrine Care

Estrogen Status Correlates with the Calcium Content of Coronary Atherosclerotic Plaques in Women

R. C. Christian, S. Harrington, W. D. Edwards, A. L. Oberg and L. A. Fitzpatrick

Division of Endocrinology, Metabolism, and Nutrition, Department of Internal Medicine (R.C.C., S.H., L.A.F.), Department of Anatomic Pathology (W.D.E.), Department of Health Sciences Research (A.L.O.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905

Address all correspondence and requests for reprints to: Lorraine A. Fitzpatrick, M.D., Endocrine Research Unit, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905. E-mail: . fitz{at}mayo.edu

Abstract

Background: Coronary artery calcium, a radiographic marker for atherosclerosis and a predictor of coronary heart disease (CHD), is less extensive in women than in men of the same age. The role of estrogen in the pathogenesis of coronary artery calcification is unknown. We examined the association of estrogen status with extent of calcification and atherosclerotic plaque in coronary arteries of deceased women.

Methods: Coronary arteries were obtained at autopsy from 56 white women age 18–98 yr, 46 postmenopausal and 10 premenopausal. Exclusion criteria included patients with coronary stents, coronary artery bypass surgery, and medical-legal cases. Medical records were reviewed for demographics, CHD risk factors, menstrual status, and use of estrogen replacement therapy. Contact microradiography of coronary arteries assessed true calcium content and atherosclerotic plaque area was analyzed histologically.

Results: The coronary arteries from estrogen-treated postmenopausal women had lower mean coronary calcium content (P = 0.002), mean plaque area (P < 0.0001), and calcium-to-plaque area ratio (P = 0.004) than those from untreated menopausal women. Estrogen status, age, diabetes, and hypertension predicted calcium and plaque area by univariate analysis. After controlling for these CHD risk factors, estrogen status remained an independent predictor of both calcium (P = 0.014) and plaque area (P = 0.001) in all women. Mean calcium area (P < 0.05) but not plaque area (P = 0.44) was significantly greater in women treated with estrogen replacement therapy than in premenopausal women. Coronary calcium (P < 0.007) and plaque area (P < 0.03) varied significantly with age in untreated postmenopausal women, but not in the estrogen-treated or premenopausal women (P = 0.33).

Conclusions: Estrogen status is associated with coronary calcium and plaque area independent of age and CHD risk factors. Estrogen may modulate the calcium content of atherosclerotic plaques, as well as plaque area and may slow the progression of atherosclerosis in women.




This article has been cited by other articles:


Home page
NEJMHome page
H. N. Hodis, W. J. Mack, M. A. Brouwer, H.-J. Dieker, F. W.A. Verheugt, L. C. Hofbauer, S. Khosla, M. Schoppet, J. E. Manson, M. A. Allison, et al.
Estrogen Therapy and Coronary-Artery Calcification
N. Engl. J. Med., September 20, 2007; 357(12): 1252 - 1254.
[Full Text] [PDF]


Home page
Circ. Res.Home page
A. P. V. Dantas and K. Sandberg
Does 2-Methoxyestradiol Represent the New and Improved Hormone Replacement Therapy for Atherosclerosis?
Circ. Res., August 4, 2006; 99(3): 234 - 237.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. C. Christian, P. Y. Liu, S. Harrington, M. Ruan, V. M. Miller, and L. A. Fitzpatrick
Intimal Estrogen Receptor (ER){beta}, But Not ER{alpha} Expression, Is Correlated with Coronary Calcification and Atherosclerosis in Pre- and Postmenopausal Women
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2713 - 2720.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. H. E. M. Maas, Y. T. van der Schouw, D. Beijerinck, J. J. M. Deurenberg, W. P. T. M. Mali, and Y. van der Graaf
Arterial Calcifications Seen on Mammograms: Cardiovascular Risk Factors, Pregnancy, and Lactation
Radiology, July 1, 2006; 240(1): 33 - 38.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
E. Rzewuska-Lech, M. Jayachandran, L. A. Fitzpatrick, and V. M. Miller
Differential effects of 17{beta}-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins
Am J Physiol Endocrinol Metab, July 1, 2005; 289(1): E105 - E112.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, R. C. Christian, M. Ruan, V. M. Miller, and L. A. Fitzpatrick
Correlating Androgen and Estrogen Steroid Receptor Expression with Coronary Calcification and Atherosclerosis in Men without Known Coronary Artery Disease
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1041 - 1046.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth
Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification
Endocr. Rev., August 1, 2004; 25(4): 629 - 672.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Abedin, Y. Tintut, and L. L. Demer
Vascular Calcification: Mechanisms and Clinical Ramifications
Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1161 - 1170.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Miwa, M. Tsushima, H. Arima, Y. Kawano, and T. Sasaguri
Pulse Pressure Is an Independent Predictor for the Progression of Aortic Wall Calcification in Patients With Controlled Hyperlipidemia
Hypertension, March 1, 2004; 43(3): 536 - 540.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Maffei, Y. Murata, V. Rochira, G. Tubert, C. Aranda, M. Vazquez, C. D. Clyne, S. Davis, E. R. Simpson, and C. Carani
Dysmetabolic Syndrome in a Man with a Novel Mutation of the Aromatase Gene: Effects of Testosterone, Alendronate, and Estradiol Treatment
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 61 - 70.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. A. Fitzpatrick
Hormones and the Heart: Controversies and Conundrums
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5609 - 5610.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Akhrass, A. T. Evans, Y. Wang, S. Rich, C. R. Kannan, L. Fogelfeld, and T. Mazzone
Hormone Replacement Therapy Is Associated with Less Coronary Atherosclerosis in Postmenopausal Women
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5611 - 5614.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Fournier, C. Presne, R. Oprisiu, and T. Sadek
Oral calcium, sevelamer and vascular calcification in uraemic patients
Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2276 - 2277.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Bidder, J.-S. Shao, N. Charlton-Kachigian, A. P. Loewy, C. F. Semenkovich, and D. A. Towler
Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells Is Controlled by Glucose-regulated Upstream Stimulatory Factor and Activator Protein-1 Activities
J. Biol. Chem., November 8, 2002; 277(46): 44485 - 44496.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society